Replies to post #5650 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

Those are question you should have asked yourself before acquiring first time. Nothing has changed regarding the data and KIT-302 value.

ISA investigation regarded "dissemination" of data.

So .... we all should understand that we have not invested in Pfizer .... Kitov is a Israeli nano cap with approx 5 employees and with very promising drugs, one of them a potential blockbuster that successfully passed phase 3. If you check the filing you could find out many reasons that could explain the delays .... the requested did by FDA in the pre-meeting NDA for example. In the meanwhile, after data results, during 2016, KIT-302 has been patented ....

What I'm trying to say you is that if you believed in KIT-302 and Waymack before, there is not reason you shouldn't now.

Kitov potential has been reviewed several time by Dexcel (that recently asked for filing a patent application together), by Kunhil Pharma and the last one by GHP partners (Gil Pogozelich recently sold a company he owned for more than $20mm), that accepted to sell Tyrnovo for Kitov shares and now owns 6,8% stake in Kitov (and this is not just an asset, this is science, years of work and research .... Alexander Levitzki says you something?) ....

More reasons to be optimistic. Lot of catalysts ahead.

All the best.

[tykundegex]

The same question could be asked of ANY stock that rose 200%, 500%, or 1000% over a relatively short period. But it happens all the time, and it's usually because there is still too much risk for most investors, and the rise is fueled by speculation or an event that de-risks the investment. I'm expecting the latter will happen in the next 6-12 months.

Buying shares in KTOV is not without risk. But stocks with low risk can't yield the same potential gains.

Let me ask you this, if so many opportunities people can see it, then why KTOV trading at $1.8s?